| # | Title | Journal | Year | Citations |
|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer | New England Journal of Medicine | 2005 | 4,601 |
| 2 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Lancet, The | 2014 | 3,224 |
| 3 | The landscape of cancer genes and mutational processes in breast cancer | Nature | 2012 | 1,535 |
| 4 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 | Annals of Oncology | 2015 | 1,449 |
| 5 | Gene-Expression Signatures in Breast Cancer | New England Journal of Medicine | 2009 | 1,286 |
| 6 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Lancet, The | 2012 | 1,165 |
| 7 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer | Lancet, The | 1998 | 958 |
| 8 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study | Lancet, The | 2011 | 949 |
| 9 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients | British Journal of Cancer | 2007 | 763 |
| 10 | Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes | Clinical Cancer Research | 2008 | 745 |
| 11 | Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade | Journal of Clinical Oncology | 2007 | 711 |
| 12 | Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial | Lancet, The | 2016 | 695 |
| 13 | Evaluation of the Infinium Methylation 450K technology | Epigenomics | 2011 | 514 |
| 14 | International quality of life assessment (IQOLA) project | Quality of Life Research | 1992 | 512 |
| 15 | ESMO-Magnitude of Clinical Benefit Scale version 1.1 | Annals of Oncology | 2017 | 451 |
| 16 | Clinical Application of the 70-Gene Profile: The MINDACT Trial | Journal of Clinical Oncology | 2008 | 449 |
| 17 | Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? | Nature Reviews Cancer | 2007 | 423 |
| 18 | Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy | Proceedings of the National Academy of Sciences of the United States of America | 2011 | 413 |
| 19 | Clinical management of breast cancer heterogeneity | Nature Reviews Clinical Oncology | 2015 | 400 |
| 20 | Mesenchymal Stem Cells Derived from CD133-Positive Cells in Mobilized Peripheral Blood and Cord Blood: Proliferation, Oct4 Expression, and Plasticity | Stem Cells | 2005 | 390 |
| 21 | Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors | Oncologist | 2007 | 386 |
| 22 | Chromogenic in Situ Hybridization | American Journal of Pathology | 2000 | 356 |
| 23 | Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2011 | 350 |
| 24 | PIK3CAmutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer | Proceedings of the National Academy of Sciences of the United States of America | 2010 | 324 |
| 25 | Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours | British Journal of Cancer | 2005 | 321 |
| 26 | Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer | Nature Medicine | 2010 | 301 |
| 27 | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen | BMC Genomics | 2008 | 300 |
| 28 | A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis | Clinical Infectious Diseases | 2006 | 295 |
| 29 | Translocation-positive Low-grade Fibromyxoid Sarcoma: Clinicopathologic and Molecular Analysis of a Series Expanding the Morphologic Spectrum and Suggesting Potential Relationship to Sclerosing Epithelioid Fibrosarcoma | American Journal of Surgical Pathology | 2007 | 293 |
| 30 | A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer | Clinical Cancer Research | 2008 | 283 |
| 31 | Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites | Annals of Oncology | 2002 | 276 |
| 32 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study | Breast Cancer Research and Treatment | 2009 | 260 |
| 33 | The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | European Respiratory Journal | 2002 | 255 |
| 34 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program | Annals of Oncology | 2018 | 246 |
| 35 | Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study | Osteoporosis International | 2004 | 240 |
| 36 | Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement | Annals of Oncology | 2012 | 233 |
| 37 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group | Modern Pathology | 2016 | 230 |
| 38 | Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies | European Journal of Cancer | 2011 | 227 |
| 39 | Immune evasion before tumour invasion in early lung squamous carcinogenesis | Nature | 2019 | 227 |
| 40 | Long-term toxic effects of adjuvant chemotherapy in breast cancer | Annals of Oncology | 2011 | 221 |
| 41 | Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer | PLoS ONE | 2011 | 214 |
| 42 | DNA methylation profiling reveals a predominant immune component in breast cancers | EMBO Molecular Medicine | 2011 | 210 |
| 43 | Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases | Diagnostic Pathology | 2014 | 200 |
| 44 | Sunscreen Use, Wearing Clothes, and Number of Nevi in 6- to 7-Year-Old European Children | Journal of the National Cancer Institute | 1998 | 196 |
| 45 | Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome | Cell Reports | 2015 | 179 |
| 46 | Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? | European Journal of Cancer | 2006 | 173 |
| 47 | Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors | Genes Chromosomes and Cancer | 2010 | 172 |
| 48 | Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An eortc multicenter case-control study in Belgium, France and Germany | International Journal of Cancer | 1994 | 166 |
| 49 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data | Lancet Oncology, The | 2011 | 165 |
| 50 | Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial | Annals of Oncology | 2009 | 163 |
